Clinical observation of combined transarterial chemoembolization and targeted therapy in postoperative recurrent colorectal cancer with liver metastasis

Table 1 Baseline characteristics of the study population

Characteristic	n (%)
Sex
Male	45 (60)
Female	30 (40)
Age, years	58 (35-75)
Primary tumor location
Colon	40 (53.3)
Rectum	35 (46.7)
Initial AJCC stage
Stage III	20 (26.7)
Stage IV	55 (73.3)
Disease-free interval, months	24 (6-60)
Liver metastases
Solitary	30 (40)
Multiple	45 (60)
Number of metastases	3 (1-10)
Average size of metastases, cm	4.5 ± 1.8
Location of metastases
Right lobe	41 (55)
Left lobe	23 (30)
Both lobes	11 (15)
Molecular profiling
KRAS mutation	35 (46.7)
NRAS mutation	15 (20)
Wild-type RAS	25 (33.3)
VEGF overexpression	50 (66.7)
EGFR expression	40 (53.3)
Prior treatments
Systemic chemotherapy	20 (26.7)
Targeted therapy	10 (13.3)

AJCC: American Joint Committee on Cancer; RAS: Rat sarcoma viral oncogene homolog; VEGF: Vascular endothelial growth factor; EGFR: Epidermal growth factor receptor.